Now that we have got the green lights from the FDA to proceed with the trials and it makes logical sense to dual list the shares registry to Nasdaq to facilitate domestic partnerships (distribution and development etc) in the US, joint ventures and/or commercialisation much sooner.
Funding won’t be an issue for us anymore given the FDA clearance and pathway, groundbreaking next generation technology in an expanding market covering younger patients, and the new income stream as well as reimbursement from the trials and R&D.
The share price will reflect the intrinsic value very soon I reckon.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)